Business
Kate Priestman appointed as Non-Executive Director
Kate Priestman appointed as Non-Executive Director.
About this update from Oxford Nanopore Technologies Plc
[{"type":"text","content":"\n\n13 July 2023\nOxford Nanopore Technologies plc\nKate Priestman appointed as Non-Executive Director\nOxford Nanopore Technologies plc (LSE: ONT) (\"Oxford Nanopore\" or \"the Group\"), the company delivering a new generation of nanopore-based molecular sensing technology, is pleased to announce that Kate Priestman will be joining the Group as Non-Executive Director with effect from 13 July 2023.\nOxford Nanopore's molecular sensing platform is increasingly a technology of choice in life science-based industries and applications, from biopharma and clinical to agriculture and food. Kate brings extensive experience as a biopharma executive for more than 25 years, serving in leadership roles across commercial, operations, corporate strategy, communications and government affairs. She was most recently Senior Vice President of R&D Strategy, Portfolio and Operations at GlaxoSmithKline, where she led the evolution of GSK's science and technology strategy, portfolio management and global R&D operations & business transformation, helping steer the FTSE 100 company's growth. Kate also served on GSK's separation board, delivering the successful spin-out of Haleon plc in 2022.\nIn addition, she previously held global and UK roles at Eli Lilly & Co and Zeneca, after an early career at the BBC, where she spent several years as a broadcaster. Kate also currently also serves as a Trustee of RBG Kew, an organisation with around 500 scientists working globally to understand plant biology and fight biodiversity loss.\nDuncan Tatton-Brown, Chair of Oxford Nanopore, said: \"We are extremely pleased to welcome Kate as a Non-Executive Director of Oxford Nanopore. Kate's impressive track-record of working with a UK-headquartered, global leader in biopharma, along with her other extensive experience, uniquely positions her to understand and support the next phase of growth for Oxford Nanopore. Kate understands this opportunity better than most, and we look forward to working with her as Oxford Nanopore starts to expand beyond life science research into additional clinical and applied markets.\"\nKate Priestman, incoming Non-Executive Director of Oxford Nanopore, said: \"I am excited to join Oxford Nanopore at this pivotal juncture in its growth journey. Oxford Nanopore has an incredible opportunity with its technology that has the po...